Royalty Report: Coating, Device, Chemicals – Collection: 243410


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Coating
  • Device
  • Chemicals
  • Drugs
  • Catheter
  • Disease
  • Therapeutic
  • Medical
  • Surgical
  • Stent

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 243410

License Grant
For the Development License, Licensor grants a non-exclusive right and license in the Territory, without the right to grant sublicenses, under Licensors rights in Licensor Intellectual Property, to make and use Licensor Nitric Oxide Releasing Compounds in the course of the R&D Program to develop Royalty-Bearing Products.

For the Commercialization Licenses, Licensor grants to Licensee
– an exclusive right and license in the Territory, with the right to grant sublicenses, under Licensors rights in Licensor Intellectual Property and Joint Intellectual Property, to make, use, sell, offer to sell and import Royalty-Bearing Products incorporating Licensor Delivered Compounds; and
– a non-exclusive right and license in the Territory, with the right to grant sublicenses, under Licensors rights in the Licensors Intellectual Property other than the Licensor Composition Patent Rights, to make, use, sell, offer to sell and import Royalty-Bearing Products incorporating Limited License Compounds.

License Property
Licensor discovers and develops nitric oxide releasing compounds for use in drug products and medical devices.

Product shall mean a medical device or a specialty catheter product developed for use in the Field, in either case incorporating one or more Licensor Nitric Oxide Releasing Compounds.  Nitric Oxide Releasing Compounds shall mean compounds that donate, release and/or directly or indirectly transfer nitrogen monoxide, such that the biological activity of the nitrogen monoxide is expressed at an intended site of action.

Product relates to stents coated with nitric oxide-releasing compounds.

Field of Use
The Field shall mean the localized delivery to vascular walls in humans of Nitric Oxide Releasing Compounds for the treatment, reduction or inhibition of restinosis using coated medical devices or delivered via specialty catheters.

This development and license agreement is for the research, development and commercialization of cardiovascular stents coated with nitric oxide-enhancing medicines. Stents, or wire mesh devices, are typically inserted into narrowed coronary arteries to maintain blood flow.

IPSCIO Record ID: 5512

License Grant
The Licensor hereby grants to the Licensee the exclusive worldwide license for certain patented technologies marketed under the trade names PROstent (TM) and Liprostin / PROstent (TM), and the Licensor's referenced technologies with multiple stent coating applications for use with other medical devices, including catheter delivery of PROstent.
License Property
The technology being licensed includes Patent Application No. 09/309,949; Filed on May 11, 1999; 'Prosthesis With Biodegradable Surface Coating and Method For Making Same.' This application is a continuation-in-part application of U.S. Patent Application Serial No. 08/797,743 filed on February 7, 1997.
Abstact A vascular structure includes suitable mechanical properties needed to open and maintain a vessel, duct, tract, or organ and precise chronicity controlling the release and delivery of a bioactive agent carried on the vascular structure. The bioactive agent is capable of acting upon and altering the mechanisms of biologic systems in a manner providing a medicinal therapy. The vascular structure includes at least one layer or coating of the bioactive agent overlaid by a permiable membrane for controlling the osmotic release of the bioactive agent.

Technology also includes Patent Application Serial No. 08/797,743; Filed on February 7, 1997; 'Composition and Method For Making a Biodegradable Drug Delivery Stent'.  Licensee is from Canada and licensor from U.S.
Abstract A stent or vascular graft for supporting a blood vessel or organ lumen is coated with a biodegradable, resorbable and hemocompatible surface substrate. Biologically active microspheres which controllably release the biologically active agent into the vessel wall or organ to inhibit restenosis of the stent is embedded in the stent substrate. The biologically active microspheres include encapsulated PGE1 in a water soluble polyethylene glycol mix, which over a period of time dissolves and releases the PGE1 into the vessel wall or organ.

USE OF TRADEMARKS. The Licensee will be allowed to use any and all trademarks of the Licensor with respect to the Technology, Products and any Improvements.

IPSCIO Record ID: 209508

License Grant
Licensor, of the Netherlands, grants a non-exclusive, worldwide license to import, export, use, sell, and offer for sale Licensees Stents utilizing, incorporating or coated with Licensors Drug/Polymer Composite Formulation, Biolimus A9 and/or Licensors Polymer Coating in Licensees Licensed Field of Use; and

At Licensees option, a non-exclusive, worldwide license to import, export, use, sell, and offer for sale Licensee Stent Systems incorporating or utilizing Licensors Lubricious Coating.

License Property
The Coated Stents means Licensees Stents marketed, developed or sold by Licensee and coated with Licensors Polymer Coating, Occams Drug/Polymer Composite Formulation, or Biolimus A9.

The Covered Products means either or both Coated Stents and Licensee Stent Systems incorporating or utilizing Licensors Lubricious Coating.

The patents relate to Endovascular Stents and coatings.

Biolimus A9 is formulated to inhibit excessive tissue formation around the stent following implantation, a common side effect called restenosis which often threatens to reverse the clinical benefits of the angioplasty and stent implantation procedures.

Field of Use
Licensees Licensed Field of Use means any applications, procedures, processes or other uses related to drug-eluting, commonly delivered Stents that are delivered as a series of short stents on a delivery catheter wherein the operator has the ability to select the number of short stents as a portion of the total number of stents in the series to be deployed, solely for use in coronary and peripheral vascular applications.

In Japan, Licensees Licensed Field of Use is further limited to treating long lesions, multiple vessels or small vessels in coronary and peripheral applications.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.